NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

OCUL

Ocular Therapeutix Inc

Jul 11 • 04:00PM ET

11.03

Dollar change -0.05
Percentage change -0.45	%

Healthcare • Biotechnology • USA • NASD

Peers: LLY GILD JNJ AMGN BIIB BMRN ALKS INCY AGIO ELAN

| Held by: IWM VTI VXF IWO PJP SCHA VTWO IHE XPH DWAS

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.15	Insider Own	16.33%	Shs Outstand	159.26M	Perf Week	14.66%
Market Cap	1.76B	Forward P/E	-	EPS next Y	-1.39	Insider Trans	-0.31%	Shs Float	133.28M	Perf Month	23.79%
Enterprise Value	1.48B	PEG	-	EPS next Q	-0.35	Inst Own	74.22%	Short Float	10.63%	Perf Quarter	61.26%
Income	-192.71M	P/S	29.46	EPS this Y	-17.19%	Inst Trans	21.73%	Short Ratio	6.54	Perf Half Y	21.48%
Sales	59.65M	P/B	6.61	EPS next Y	2.56%	ROA	-40.79%	Short Interest	14.17M	Perf YTD	29.16%
Book/sh	1.67	P/C	5.02	EPS next 5Y	4.11%	ROE	-57.19%	52W High	11.77 -6.33%	Perf Year	71.01%
Cash/sh	2.20	P/FCF	-	EPS past 3/5Y	-7.77% 8.51%	ROIC	-56.68%	52W Low	5.78 90.67%	Perf 3Y	157.71%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	13.55% 72.05%	Gross Margin	90.67%	Volatility	5.48% 5.71%	Perf 5Y	46.09%
Dividend TTM	-	EV/Sales	24.87	EPS Y/Y TTM	-3.59%	Oper. Margin	-342.15%	ATR (14)	0.55	Perf 10Y	-45.26%
Dividend Ex-Date	-	Quick Ratio	10.14	Sales Y/Y TTM	-0.33%	Profit Margin	-323.09%	RSI (14)	76.74	Recom	1.08
Dividend Gr. 3/5Y	- -	Current Ratio	10.22	EPS Q/Q	23.03%	SMA20	18.36%	Beta	1.48	Target Price	17.92
Payout	-	Debt/Eq	0.29	Sales Q/Q	-27.59%	SMA50	30.99%	Rel Volume	0.98	Prev Close	11.08
Employees	274	LT Debt/Eq	0.28	Earnings	May 05 BMO	SMA200	29.51%	Avg Volume	2.17M	Price	11.03
IPO	Jul 25, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	-29.08% -37.15%	Trades		Volume	2,132,512	Change	-0.45%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-08-25	Initiated	William Blair	Outperform
Mar-18-25	Initiated	RBC Capital Mkts	Outperform	$17
Mar-11-25	Initiated	Needham	Buy	$15
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Jun-20-24	Upgrade	TD Cowen	Hold → Buy	$7 → $11
May-31-24	Resumed	Piper Sandler	Overweight	$15
Feb-09-24	Initiated	BofA Securities	Buy	$15
Apr-21-23	Initiated	Robert W. Baird	Outperform	$18
Aug-10-22	Resumed	Berenberg	Buy	$15
Aug-10-21	Upgrade	H.C. Wainwright	Neutral → Buy	$17
Dec-28-20	Downgrade	H.C. Wainwright	Buy → Neutral
Dec-17-20	Initiated	Berenberg	Buy	$27
Nov-13-20	Reiterated	Raymond James	Strong Buy	$15 → $25
Aug-10-20	Reiterated	H.C. Wainwright	Buy	$10 → $13
Mar-03-20	Upgrade	Raymond James	Outperform → Strong Buy
May-21-19	Reiterated	H.C. Wainwright	Buy	$12 → $9
May-21-19	Downgrade	Raymond James	Strong Buy → Outperform	$11 → $5
May-21-19	Downgrade	Cowen	Outperform → Market Perform	$13 → $3
Dec-03-18	Reiterated	Cantor Fitzgerald	Overweight	$22 → $24
Nov-15-18	Initiated	Raymond James	Strong Buy	$10

Show Previous Ratings

Jun-26-25 01:54PM	Ocular Therapeutix Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company (GlobeNewswire)
Jun-25-25 11:13AM	Ocular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last? (Zacks)
Jun-16-25 07:00AM	Ocular Therapeutix to Participate in Clinical Trials at the Summit (CTS) 2025 (GlobeNewswire)
May-28-25 07:00AM	Ocular Therapeutix To Close Enrollment This Week for SOL-R, its Second Registrational Trial Evaluating AXPAXLI in Wet Age-Related Macular Degeneration (GlobeNewswire) +13.69%
May-14-25 07:00AM	Ocular Therapeutix to Participate in Upcoming Investor Conferences (GlobeNewswire)
08:15AM	Loading…
May-05-25 08:15AM	Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -12.16%
07:11AM	Ocular Therapeutix: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Ocular Therapeutix Reports First Quarter 2025 Results and Business Highlights (GlobeNewswire)
May-02-25 09:25AM	Ocular Therapeutix Inc (OCUL) Q1 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Apr-29-25 10:01AM	Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for (Zacks)
07:00AM	Ocular Therapeutix to Participate in Upcoming Investor and Scientific Conferences (GlobeNewswire)
Apr-28-25 07:00AM	Ocular Therapeutix to Report First Quarter 2025 Financial Results on May 5, 2025 (GlobeNewswire) +5.45%
Apr-11-25 04:30PM	Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +11.01% +6.47%
Mar-31-25 07:00AM	Ocular Therapeutix to Participate in Two Investor Conferences in April (GlobeNewswire)
Mar-14-25 08:36AM	Why Ocular Therapeutix Was Bumping Higher This Week (Motley Fool)
02:49PM	Loading…
Mar-11-25 02:49PM	Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside (Benzinga) +11.24%
Mar-07-25 04:05PM	Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-04-25 02:00AM	Ocular Therapeutix Inc (OCUL) Q4 2024 Earnings Call Highlights: Strategic Advancements and ... (GuruFocus.com) +9.70%
Mar-03-25 11:41PM	Q4 2024 Ocular Therapeutix Inc Earnings Call (Thomson Reuters StreetEvents) -17.02%
08:15AM	Ocular Therapeutix (OCUL) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:19AM	Ocular Therapeutix: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Ocular Therapeutix Reports Fourth Quarter and Full Year 2024 Results and Business Highlights (GlobeNewswire)
Feb-28-25 07:10AM	Ocular Therapeutix Inc (OCUL) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Feb-25-25 07:00AM	Ocular Therapeutix to Present at Two Investor Conferences in March (GlobeNewswire)
Feb-24-25 07:00AM	Ocular Therapeutix to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025 (GlobeNewswire)
Feb-03-25 07:00AM	Ocular Therapeutix Announces Upcoming Presentations at the Angiogenesis, Exudation, and Degeneration 2025 Virtual Meeting (GlobeNewswire)
Jan-17-25 07:00AM	Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-14-25 07:00AM	Ocular Therapeutix Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI in NPDR (GlobeNewswire)
Jan-08-25 07:00AM	Ocular Therapeutix to Provide Corporate Update During 43rd Annual J.P. Morgan Healthcare Conference Presentation (GlobeNewswire)
Dec-13-24 07:00AM	Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:30AM	Loading…
Dec-10-24 07:30AM	Ocular Therapeutix to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-03-24 07:47AM	Ocular Therapeutix announces over 300 subjects randomized in SOL-1 (TipRanks)
Dec-02-24 07:30AM	Ocular Therapeutix Announces More Than 300 Subjects Randomized in SOL-1 (GlobeNewswire)
Nov-26-24 07:30AM	Ocular Therapeutix to Participate in December Investor and Scientific Conferences (GlobeNewswire) +7.26%
Nov-15-24 02:06AM	Ocular Therapeutix Inc (OCUL) Q3 2024 Earnings Call Highlights: Strong Financial Position and ... (GuruFocus.com) -7.66%
Nov-14-24 08:40AM	Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -6.42%
07:37AM	Ocular Therapeutix: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Ocular Therapeutix Reports Third Quarter 2024 Results and Business Highlights (GlobeNewswire)
Nov-13-24 07:30AM	Ocular Therapeutix to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV (GlobeNewswire)
07:17AM	What To Expect From Ocular Therapeutix Inc (OCUL) Q3 2024 Earnings (GuruFocus.com)
Nov-12-24 07:30AM	Ocular Therapeutix Appoints Namrata Saroj, OD, as Chief Business Officer (GlobeNewswire)
Nov-06-24 07:30AM	Ocular Therapeutix to Report Third Quarter 2024 Results on November 14, 2024 (GlobeNewswire)
Oct-15-24 07:30AM	Ocular Therapeutix Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI in Wet AMD (GlobeNewswire)
Oct-14-24 09:59AM	Ocular Therapeutix (OCUL) Moves 6.1% Higher: Will This Strength Last? (Zacks) +6.95%
Oct-09-24 04:05PM	Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:30AM	Ocular Therapeutix to Present at October Ophthalmology Meetings (GlobeNewswire)
Oct-08-24 08:50AM	Here's What Could Help Ocular Therapeutix (OCUL) Maintain Its Recent Price Strength (Zacks)
Sep-25-24 07:30AM	Ocular Therapeutix to Present at the UBS Virtual Opthalmology Day 2024 (GlobeNewswire)
Sep-12-24 04:05PM	Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-05-24 07:30AM	Ocular Therapeutix to Present at September Retina Meetings (GlobeNewswire)
Sep-04-24 07:30AM	Ocular Therapeutix to Present at Two Investor Conferences in September (GlobeNewswire)
Aug-09-24 09:55AM	Wall Street Analysts See an 85.43% Upside in Ocular Therapeutix (OCUL): Can the Stock Really Move This High? (Zacks)
07:30AM	Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-07-24 08:45AM	Ocular Therapeutix (OCUL) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +6.08%
07:38AM	Ocular Therapeutix: Q2 Earnings Snapshot (Associated Press Finance)
07:10AM	Ocular Therapeutix Reports Second Quarter 2024 Results (GlobeNewswire)
07:00AM	Ocular Therapeutix Announces FDA Feedback That SOL-R Trial is Appropriate as a Registrational Study in Wet AMD (GlobeNewswire)
Jul-31-24 07:30AM	Ocular Therapeutix to Report Second Quarter 2024 Financial Results on August 7, 2024 (GlobeNewswire)
Jul-30-24 07:30AM	Ocular Therapeutix Announces First Patients Enrolled in Phase 3 SOL-R Wet AMD Study (GlobeNewswire)
Jul-18-24 04:05PM	Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-10-24 08:00AM	Ocular Therapeutix Announces Late-Breaking Abstract of HELIOS Study to be Presented at 42nd ASRS Annual Scientific Meeting (GlobeNewswire) +11.01%
Jul-08-24 04:05PM	Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-13-24 04:05PM	Ocular Therapeutix Highlights Exceptional AXPAXLI SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day, Along with Positive 48-week Data from HELIOS NPDR Study (GlobeNewswire) +14.09%
Jun-05-24 07:30AM	Ocular Therapeutix to Host Investor Day on June 13, 2024 (GlobeNewswire)
Jun-04-24 04:05PM	Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-07-24 09:01PM	OCUL Stock Earnings: Ocular Therapeutix Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
06:07PM	Ocular Therapeutix Inc Reports First Quarter 2024 Earnings (GuruFocus.com)
04:41PM	Ocular Therapeutix: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Ocular Therapeutix Reports First Quarter 2024 Results (GlobeNewswire)
May-06-24 08:16PM	Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.00%
07:30AM	Ocular Therapeutix to Present at Two Upcoming Investor Conferences (GlobeNewswire)
May-03-24 07:30AM	Ocular Therapeutix To Present at Two Ophthalmology Meetings, May 4-9, 2024 (GlobeNewswire) +5.11%
May-01-24 07:30AM	Ocular Therapeutix to Host Investor Day in New York City on Thursday, June 13, 2024 (GlobeNewswire) +5.91%
Apr-24-24 08:30AM	2 Small-Cap Growth Stocks With Room to Run (Motley Fool) -7.10%
Apr-18-24 03:37PM	Ocular Therapeutix Highlights Early Data From Diabetes-Related Eye Disorder (Benzinga) -22.69%
07:00AM	Ocular Therapeutix Announces Positive Topline Phase 1 Data for AXPAXLI in Diabetic Retinopathy (GlobeNewswire)
Apr-16-24 04:30PM	The 3 Best Biotech Stocks to Buy Now: Q2 Edition (InvestorPlace)
07:00AM	Ocular Therapeutix Strengthens Clinical Team with Appointment of Key Retinal Leaders (GlobeNewswire)
Apr-15-24 07:00AM	Ocular Therapeutix Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO (GlobeNewswire)
Apr-09-24 09:35AM	Down -17.88% in 4 Weeks, Here's Why Ocular Therapeutix (OCUL) Looks Ripe for a Turnaround (Zacks)
07:30AM	Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics (GlobeNewswire)
Apr-06-24 10:00AM	Ocular Therapeutix Announces Positive Phase 2 PAXTRAVA Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting (GlobeNewswire)
Apr-01-24 10:09AM	Million-Dollar Bets: 3 Under-$15 Stocks With Massive Potential (InvestorPlace)
Mar-26-24 07:30AM	Ocular Therapeutix To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery) (GlobeNewswire)
Mar-13-24 06:38AM	Q4 2023 Clearside Biomedical Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-12-24 09:55AM	Wall Street Analysts Think Ocular Therapeutix (OCUL) Could Surge 34.74%: Read This Before Placing a Bet (Zacks)
Mar-11-24 05:32PM	Ocular Therapeutix Inc Reports Growth Amidst Strategic Shifts (GuruFocus.com)
05:25PM	Ocular Therapeutix (OCUL) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:26PM	Ocular Therapeutix: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Ocular Therapeutix Reports Fourth Quarter and Full Year 2023 Results (GlobeNewswire)
Mar-05-24 07:30AM	Ocular Therapeutix to Release Fourth Quarter and Full Year 2023 Results on March 11, 2024 (GlobeNewswire)
Mar-01-24 06:30PM	Criteo, Ocular Therapeutix, and More Stocks See Action From Activist Investors (Barrons.com) +6.86%
Feb-29-24 08:52AM	Should You Buy Ocular Therapeutix (OCUL) Ahead of Earnings? (Zacks)
Feb-28-24 01:40PM	Hedge Fund and Insider Trading News: Stan Druckenmiller, Warren Buffett, Brevan Howard Asset Management, Citadel LLC, AMN Healthcare Services Inc (AMN), Ocular Therapeutix Inc (OCUL), and More (Insider Monkey)
Feb-26-24 12:00PM	Are You Looking for a Top Momentum Pick? Why Ocular Therapeutix (OCUL) is a Great Choice (Zacks)
10:00AM	Ocular Therapeutix (OCUL) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Feb-25-24 02:02PM	3 Stocks to Buy That Are Up 100% or More in 2024 (InvestorPlace)
Feb-22-24 07:32AM	Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Chairman and Chief Strategy Officer (GlobeNewswire) +28.99%
07:31AM	Ocular Therapeutix, Inc. Announces $325.0 Million Private Placement (GlobeNewswire)
07:30AM	Ocular Therapeutix Announces Board of Directors and Leadership Updates (GlobeNewswire)

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Waheed Nadia	Chief Medical Officer	Jun 02 '25	Sale	8.05	13,861	111,581	206,805	Jun 03 04:20 PM
NADIA K. WAHEED	Officer	Jun 02 '25	Proposed Sale	8.05	13,861	111,524		Jun 02 04:40 PM
Nayak Sanjay	Chief Strategy Officer	May 23 '25	Sale	7.17	1,862	13,351	281,623	May 27 05:42 PM
Kaiser Peter	Chief Development Officer	May 23 '25	Sale	7.17	2,974	21,324	207,104	May 27 05:40 PM
Heier Jeffrey S.	Chief Scientific Officer	May 23 '25	Sale	7.18	3,024	21,712	262,974	May 27 05:39 PM
Dugel Pravin	See Remarks	May 23 '25	Sale	7.18	21,219	152,352	3,499,099	May 27 05:37 PM
PETER KAZUO KAISER	Officer	May 23 '25	Proposed Sale	7.17	2,974	21,323		May 23 04:14 PM
JEFFREY S. HEIER	Officer	May 23 '25	Proposed Sale	7.18	3,024	21,707		May 23 04:11 PM
PRAVIN DUGEL	Officer	May 23 '25	Proposed Sale	7.18	21,219	152,289		May 23 04:08 PM
SANJAY NAYAK	Officer	May 23 '25	Proposed Sale	7.17	1,862	13,347		May 23 04:07 PM
LINDSTROM RICHARD L MD	Director	May 08 '25	Buy	6.96	10,000	69,600	172,704	May 12 08:50 PM
Dugel Pravin	See Remarks	Feb 24 '25	Sale	6.87	21,475	147,533	3,520,318	Feb 26 06:27 PM
Heier Jeffrey S.	Chief Scientific Officer	Feb 24 '25	Sale	6.87	3,061	21,029	265,998	Feb 26 06:25 PM
Kaiser Peter	Chief Development Officer	Feb 24 '25	Sale	6.87	3,009	20,672	210,078	Feb 26 06:24 PM
Nayak Sanjay	Chief Strategy Officer	Feb 24 '25	Sale	6.84	1,895	12,962	283,485	Feb 26 06:22 PM
PETER KAZUO KAISER	Officer	Feb 24 '25	Proposed Sale	6.87	3,009	20,684		Feb 24 04:54 PM
JEFFREY S. HEIER	Officer	Feb 24 '25	Proposed Sale	6.87	3,061	21,043		Feb 24 04:33 PM
PRAVIN DUGEL	Officer	Feb 24 '25	Proposed Sale	6.87	21,475	147,617		Feb 24 04:32 PM
SANJAY NAYAK	Officer	Feb 24 '25	Proposed Sale	6.84	1,895	12,957		Feb 24 04:30 PM
Notman Donald	See Remarks	Feb 04 '25	Sale	7.81	11,119	86,839	193,444	Feb 04 07:16 PM
Notman Donald	See Remarks	Jan 31 '25	Sale	7.84	6,301	49,400	204,563	Feb 04 07:16 PM
DONALD D NOTMAN JR.	Officer	Feb 04 '25	Proposed Sale	7.81	11,119	86,809		Feb 04 04:24 PM
DONALD D NOTMAN JR.	Officer	Jan 31 '25	Proposed Sale	7.84	6,301	49,404		Jan 31 04:24 PM
Heier Jeffrey S.	Chief Scientific Officer	Nov 25 '24	Sale	9.01	2,948	26,561	269,059	Nov 27 07:52 AM
Kaiser Peter	Chief Development Officer	Nov 25 '24	Sale	9.01	2,897	26,102	213,087	Nov 27 07:51 AM
Nayak Sanjay	Chief Strategy Officer	Nov 25 '24	Sale	9.00	1,814	16,326	174,380	Nov 27 07:49 AM
Dugel Pravin	See Remarks	Nov 25 '24	Sale	9.01	20,680	186,327	791,793	Nov 27 07:47 AM
SANJAY NAYAK	Officer	Nov 25 '24	Proposed Sale	8.97	1,814	16,273		Nov 25 06:42 PM
PETER KAZUO KAISER	Officer	Nov 25 '24	Proposed Sale	9.01	2,897	26,095		Nov 25 06:23 PM
PRAVIN DUGEL	Officer	Nov 25 '24	Proposed Sale	9.01	17,783	160,186		Nov 25 06:19 PM
PRAVIN DUGEL	Officer	Nov 25 '24	Proposed Sale	9.01	2,897	26,095		Nov 25 05:44 PM
JEFFREY S. HEIER	Officer	Nov 25 '24	Proposed Sale	9.01	2,948	26,550		Nov 25 05:10 PM
PHILIP C. STRASSBURGER	Officer	Oct 16 '24	Proposed Sale	10.23	13,125	134,269		Oct 16 04:25 PM
Nayak Sanjay	Chief Strategy Officer	Aug 23 '24	Sale	9.02	1,832	16,525	176,194	Aug 27 05:19 PM
Dugel Pravin	See Remarks	Aug 23 '24	Sale	9.02	20,880	188,338	812,473	Aug 27 05:17 PM
RABIA OZDEN	Officer	Aug 27 '24	Proposed Sale	9.00	18,333	164,997		Aug 27 04:18 PM
PRAVIN DUGEL	Officer	Aug 23 '24	Proposed Sale	9.02	20,880	188,271		Aug 23 05:10 PM
SANJAY NAYAK	Officer	Aug 23 '24	Proposed Sale	9.02	1,832	16,526		Aug 23 04:36 PM
RABIA OZDEN	Officer	Aug 21 '24	Proposed Sale	8.90	10,000	89,047		Aug 21 05:32 PM
RABIA OZDEN	Officer	Aug 07 '24	Proposed Sale	8.50	15,000	127,500		Aug 07 04:15 PM
ANTONY MATTESSICH	Former Officer	Aug 01 '24	Proposed Sale	8.19	23,979	196,498		Aug 01 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

OCUL

Ocular Therapeutix Inc

Upgrade your FINVIZ experience